These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29182623)

  • 1. Immunotherapeutic efficacy of liposome-encapsulated refined allergen vaccines against Dermatophagoides pteronyssinus allergy.
    Chaisri U; Tungtrongchitr A; Indrawattana N; Meechan P; Phurttikul W; Tasaniyananda N; Saelim N; Chaicumpa W; Sookrung N
    PLoS One; 2017; 12(11):e0188627. PubMed ID: 29182623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal, liposome-adjuvanted cockroach allergy vaccines made of refined major allergen and whole-body extract of Periplaneta americana.
    Meechan P; Tungtrongchitr A; Chaisri U; Maklon K; Indrawattana N; Chaicumpa W; Sookrung N
    Int Arch Allergy Immunol; 2013; 161(4):351-62. PubMed ID: 23689057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of local nasal immunotherapy in allergic airway inflammation: Using urea denatured Dermatophagoides pteronyssinus.
    Yu SJ; Liao EC; Tsai JJ
    Hum Vaccin Immunother; 2015; 11(4):915-21. PubMed ID: 25933184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tregitope-linked Refined Allergen Vaccines for Immunotherapy in Cockroach Allergy.
    Prangtaworn P; Chaisri U; Seesuay W; Mahasongkram K; Onlamoon N; Reamtong O; Tungtrongchitr A; Indrawattana N; Chaicumpa W; Sookrung N
    Sci Rep; 2018 Oct; 8(1):15480. PubMed ID: 30341299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mite allergenic components on innate immune response: Synergy of protease (Group 1 & 3) and non-protease (Group 2 & 7) allergens.
    Yin SC; Liao EC; Ye CX; Chang CY; Tsai JJ
    Immunobiology; 2018; 223(6-7):443-448. PubMed ID: 29398016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse Model of Cat Allergic Rhinitis and Intranasal Liposome-Adjuvanted Refined Fel d 1 Vaccine.
    Tasaniyananda N; Chaisri U; Tungtrongchitr A; Chaicumpa W; Sookrung N
    PLoS One; 2016; 11(3):e0150463. PubMed ID: 26954254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Engineered Hybrid Protein from
    Martínez D; Munera M; Cantillo JF; Wortmann J; Zakzuk J; Keller W; Caraballo L; Puerta L
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Profile Sensitization to House Dust Mites as an Important Aspect for Predicting the Efficiency of Allergen Immunotherapy.
    Rodinkova VV; Yuriev SD; Kryvopustova MV; Mokin VB; Kryzhanovskyi YM; Kurchenko AI
    Front Immunol; 2022; 13():848616. PubMed ID: 35392080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts.
    Casset A; Mari A; Purohit A; Resch Y; Weghofer M; Ferrara R; Thomas WR; Alessandri C; Chen KW; de Blay F; Valenta R; Vrtala S
    Int Arch Allergy Immunol; 2012; 159(3):253-62. PubMed ID: 22722650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mite Molecular Profile in the Th2-Polarized Moderate-to-Severe Persistent Asthma Endotype Subjected to High Allergen Exposure.
    González-Pérez R; Poza-Guedes P; Pineda F; Forstenlechner P; Castillo M; Mederos-Luís E; Aumayr M; Matheu V; Alava-Cruz C; Sánchez-Machín I
    Int Arch Allergy Immunol; 2021; 182(1):21-31. PubMed ID: 32927455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a hybrid protein designed with segments of allergens from Blomia tropicalis and Dermatophagoides pteronyssinus.
    Martínez D; Cantillo JF; Herazo H; Wortmann J; Keller W; Caraballo L; Puerta L
    Immunol Lett; 2018 Apr; 196():103-112. PubMed ID: 29408409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
    Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
    Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
    Rondón C; Campo P; Salas M; Aranda A; Molina A; González M; Galindo L; Mayorga C; Torres MJ; Blanca M
    Allergy; 2016 Jul; 71(7):1057-61. PubMed ID: 27008542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dust mite component Analysis: Identifying key allergens components for effective immunotherapy in allergic rhinitis.
    Huang J; Xiang R; Tan L; Deng Y; Tao Z; Zhang W; Xu Y
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111111. PubMed ID: 37925948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of molecular profiling of allergen-antibody responses in HDM-immunotherapy patients.
    Nittner-Marszalska M; Kopeć A; Foks-Ciekalska A; Lata A; Bogacz-Piaseczyńska A; Rosiek-Biegus M; Zajac M; Bożek A
    Hum Vaccin Immunother; 2022 Dec; 18(7):2148815. PubMed ID: 36444880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
    Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
    Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets.
    Weghofer M; Grote M; Resch Y; Casset A; Kneidinger M; Kopec J; Thomas WR; Fernández-Caldas E; Kabesch M; Ferrara R; Mari A; Purohit A; Pauli G; Horak F; Keller W; Valent P; Valenta R; Vrtala S
    J Immunol; 2013 Apr; 190(7):3059-67. PubMed ID: 23460742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression function against environmental dust exposure after Dermatophagoides pteronyssinus immunotherapy is associated with production of specific and cross-reactive immunoglobulin G4.
    Feng M; Luo T; Xian M; Shi X; Qin R; Zeng X; Su Q; Li J
    Clin Exp Allergy; 2022 Jul; 52(7):878-887. PubMed ID: 34962673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein sequence analysis of a novel 103-kDa Dermatophagoides pteronyssinus mite allergen and prevalence of serum immunoglobulin E reactivity to rDer p 11 in allergic adult patients.
    Lee CS; Tsai LC; Chao PL; Lin CY; Hung MW; Chien AI; Chiang YT; Han SH
    Clin Exp Allergy; 2004 Mar; 34(3):354-62. PubMed ID: 15005727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.